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Exposure to antipsychotics and risk of stroke: self controlled
case series study
Ian J Douglas, research fellow, Liam Smeeth, professor of clinical epidemiology
ABSTRACT
Objectives To investigate the association between use of
typical and atypical antipsychotic drugs and incidence of
stroke in patients with and without dementia.
Design Self controlled case series.
Setting UK based electronic primary care records in the
general practice research database (GPRD).
Participants All patients registered in the database with a
recorded incident stroke and at least one prescription for
any antipsychotic drug before the end of 2002: 6790
eligible participants were identified and included in the
final analysis.
Main outcomemeasures Rate ratio for stroke in periods of
time exposed to antipsychotics compared with
unexposed periods.
ResultsUseof any antipsychotic drugwasassociatedwith
a rate ratio for stroke of 1.73 (95% confidence interval
1.60 to1.87):1.69 (1.55 to1.84) for typicalantipsychotics
and 2.32 (1.73 to 3.10) for atypical antipsychotics. In
patients receiving any antipsychotic drug, the rate ratios
were 3.50 (2.97 to 4.12) for thosewith dementia and 1.41
(1.29 to 1.55) for those without dementia.
Conclusions All antipsychotics are associated with an
increased risk of stroke, and the risk might be higher in
patients receiving atypical antipsychotics than those
receiving typical antipsychotics. People with dementia
seem to be at a higher risk of an associated stroke than
people without dementia and use of antipsychotics
should, when possible, be avoided in these patients.
INTRODUCTION
Concerns about an increased risk of stroke associated
with atypical antipsychotic drugs first arose from
limited trial data in 2002. On the basis of these results,
Health Canada and Janssen-Ortho (the manufacturer
of risperidone) issued a warning to prescribers to
highlight this issue.1 In 2004 the United Kingdom’s
Committee on Safety of Medicines (CSM) recom-
mended avoiding the use of atypical antipsychotic
drugs among people with dementia,2 although this
decision was criticised as being detrimental to care of
patients.3 Whether the risk of stroke associated with
antipsychotic drug use differs among people with and
without dementia is not known. More recently the
European Pharmacovigilance working party consid-
ered the results of published and unpublished observa-
tional studies.4 5 They concluded that there was some
weak evidence that antipsychotic drugs increase the
risk of stroke but no clear evidence that this risk was
greaterwith atypical versus conventional antipsychotic
drugs.6 The report suggested that uncontrolled con-
founding might have affected findings to date. In
particular, the underlying cardiovascular risk in people
prescribed and not prescribed antipsychotic drugs
differs in ways that are difficult to quantify and control
for.7 8
Weusedawithinpersoncase seriesdesign toassess the
risk of stroke associated with antipsychotic drugs. Using
this technique, we compared the incidence of stroke
during periods exposed and not exposed to the drugs of
interest within individual patients,9 thus eliminating
confounding between individuals. We examined
whether someorall of thepreviouslyobserved increased
risk of stroke associated with antipsychotic drug use
could be attributable to confounding,whether the risk of
stroke associated with typical and atypical antipsychotic
drugusediffers, andwhether the risk of stroke associated
with antipsychotic druguse is higher amongpeoplewith
dementia.
METHODS
General practice research database
TheGPRD(www.gprd.com)wasestablished in1987and
was originally called the value added medical systems
(VAMP) research bank.10 It currently contains informa-
tion from over six million patients registered at over
400 general practice surgeries in the UK.11 Continuous
information is recorded for each patient, including a
record of each consultation, any diagnoses made, all
prescribed medicine, and basic demographic data. The
geographical distribution and size of general practices
represented in the database are largely representative of
thepopulationofEnglandandWales, and the individuals
registeredon thedatabase are representativeof thewhole
UK population in terms of age and sex.12 The data held
are rigorously checked and regularly audited and have
beensuccessfullyused toconductover500peer reviewed
published studies. The information obtained from the
database is entirely anonymous.
Selection of participants
Patients were selected from the population registered
with the database before 2003. Eligible participants
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were all patients with a first ever incident diagnosis of
stroke at least 12 months after initial registration with
the database. To be included in the study patients had
to have had the incident stroke on or before 31
December 2002 and also to have been prescribed at
least one antipsychotic medicine before this date.
Concerns regarding the possible cerebrovascular
effects of antipsychotic drugs in elderly people began
to emerge around this time and so we did not include
information on events after this date to eliminate the
subsequent effect of possible changes in prescribing
patterns. Also, because of concerns over repeat coding
of a single event within the database, we considered
only the first ever record of a stroke as truly incident
and excluded any subsequent record from the analysis.
Self controlled case series analysis
The self controlled case series method is derived from
the cohort method and relies on intraperson compar-
isons in a population of individuals who have both the
outcome and exposure of interest. Rate ratios compare
the rate of events during exposed periods of time with
the rate during all other observed time periods.9 This
method removes the potential confounding effect of
characteristics that vary between individuals, such as
frailty and risk factors for vascular disease.
For each participant, we identified and classified all
prescriptions for antipsychotic drugs before the end of
2002. When possible, we calculated the expected
length of exposure after each prescription using
information on pack size and dosing frequency. From
all prescription records for which this information was
available, we calculated themedian length of exposure
and assumed this length for all prescriptions where
missing information prevented actual calculation.
Each individual’s observation time was then divided
into exposure periods as follows: fully exposed periods
covered by the expected length of exposure, followed
by a sequence of five 35 day periods after treatment up
to a maximum of 175 days after the expected end of a
treatment period.We included periods after treatment
as we cannot be sure when treatment stopped, and
these periods will represent a gradual shift from full
exposure, to awashoutperiod, and finally to an entirely
unexposed state. All other periods of time were
classified as baseline (unexposed). The figure shows
how we classified the follow-up time for an individual
participant with respect to exposure.We also searched
each patient’s medical record for diagnoses indicating
dementia before stroke to allow subgroup analysis in
these patients.
We estimated the relative rate ratios using condi-
tional Poisson regressionwith Stata software, version 9
(StataCorp, College Station, TX), adjusting for age at
stroke in five year bands. We assessed the impact of
exposure to any antipsychotic medication, looked at
the effect of any antipsychotic drug among patients
with and without dementia, and measured the differ-
ential effects of typical and atypical antipsychotics
among all patients and stratified by dementia status.
RESULTS
We identified 6790 eligible patients in the database
with at least one prescription for an antipsychotic drug
and a recorded incident stroke between January 1988
and the end of 2002. Of these, 905 patients were
prescribed at least one atypical antipsychotic drug and
6334 were prescribed at least one typical antipsychotic
drug during the study period. Table 1 shows the
number of patients given a prescription for the most
commonly prescribed antipsychotics in this popula-
tion. The most commonly used typical antipsychotics
were phenothiazines (5153 patients), and the most
common atypical antipsychotic drug was risperidone
(729 patients). Some 2290 (34%) patients had a single
exposure period, 2406 (35%) had between two and five
exposure periods, and the 2094 (31%) remaining had
six or more. Table 2 gives demographic details of
patients included in the study, of whom 4353 (64%)
were women. The median age at first exposure to any
antipsychotic drugwas80,whilemedianage at the time
Table 1 | Summary of antipsychotic drug prescribing in study
population
No (%) of patients with at least
one prescription
Atypical antipsychotics
No of patients 905*
Risperidone 729 (81)
Olanzapine 165 (18)
Amisulpride 39 (4)
Quetiapine 38 (4)
Typical antipsychotics
No of patients 6334*
Phenothiazine 5153 (81)
Butyrophenone (haloperidol and
benperidol)
1243 (20)
Thioxanthine (flupentixol and
zuclopenthixol)
754 (12)
Sulpiride 160 (3)
*Individuals might have been prescribed >1 drug from each category and
therefore appear in >1 row. Patients might also have been prescribed
both typical and atypical antipsychotics.
Start of
observation
period
End of
observation
period
First
antipsychotic
prescription
Baseline
period
Risk period
during exposure
Washout period(s)
up to 175 days
Pictorial representation of study design. Figure illustrates single individual prescribed
antipsychotic drug during their observation period. All participants included in analysis had at
least oneprescription for anantipsychotic druganda single incident stroke. Rate ratiospresented
are pooled estimates derived from rate of events during risk (exposed) periods divided by rate of
events during baseline periods; age is adjusted for at all stages of analysis. Incident stroke can
occur during any one of three exposure periods: baseline, exposed, or washout period
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of first recorded stroke was 81. Table 2 also shows
details of each analysis subgroup; 1423 patients had a
recorded diagnosis of dementia before the incident
stroke and these patients were slightly older than those
without dementia at the time the first antipsychotic
drug was prescribed. In total, 5885 patients received a
prescription for a typical but not an atypical anti-
psychotic drug during the study period, and 456
patients received prescriptions only for atypical anti-
psychotics. The age at first recorded antipsychotic drug
exposure was similar for patients exposed only to
typical or atypical antipsychotics. The 449 remaining
patients received prescriptions for both typical and
atypical antipsychotics. Among patients with demen-
tia, 1212 received only typical antipsychotics and 85
received only atypical antipsychotics. The median
duration of total observation period included in the
analysis was at least four years for each subgroup.
The rate ratio for stroke among all patients
prescribed any antipsychotic drug was 1.73 (95%
confidence interval 1.60 to 1.87), comparing exposed
with unexposed baseline periods (table 3). During the
periods after treatment the rate ratio fell towards unity.
During exposedperiods, the rate ratiowas 1.69 (1.55 to
1.84) for patients receiving only typical antipsychotics
and 2.32 (1.73 to 3.10) for patients receiving only
atypical antipsychotics. During periods of treatment
withanyantipsychotic drug the rate ratiowas3.50 (2.97
to 4.12) in patients with recorded dementia before
stroke and 1.41 (1.29 to 1.55) in patients with no record
of dementia before stroke. In patients with dementia
and only typical antipsychotic drug prescriptions, the
rate ratio for stroke was 3.26 (2.73 to 3.89). This
compareswith a figureof5.86 (3.01 to11.38) inpatients
with dementia and only treated with atypical anti-
psychotics. Patients without dementia before stroke
and receiving only typical antipsychotics had a rate
ratio of 1.40 (1.26 to 1.54) compared with a figure of
1.90 (1.36 to 2.65) in patients without dementia and
receiving only atypical antipsychotics. In all analysis
subgroups, the rate ratio for stroke subsequently fell
towards unity during the phase after treatment.
DISCUSSION
The previously observed increased risk of stroke
associated with use of antipsychotic drugs is not
attributable to differences in baseline cardiovascular
risk between people prescribed and not prescribed
these drugs.The riskof stroke is slightly higherwithuse
of atypical rather than typical antipsychotic drugs. The
magnitude of the increased risk of stroke associated
with antipsychotic drug use is more than twice as great
among people with dementia compared with those
without.
Strengths and weaknesses
A key advantage of this study is the use of the self
controlled case series design, which is much less prone
to problems of confounding than traditional case-
control or cohort designs.Differencesbetweenpatients
are of little relevance as the risk comparisons are made
entirely within patients. Also, the self controlled case
series is more efficient than other observational study
designs and so more precise estimates of effects can be
made. We chose to censor follow-up for all patients at
the end of 2002 as this was when concerns about the
effects of antipsychotic drugs in patients with dementia
first emerged. This should avoid possible biases arising
from altered prescribing habits in the light of these
findings.
Other main strengths of the study were that it was
largeand statisticallypowerful.Our studywasbasedon
routine clinical data from the UK general practice
researchdatabase,which is largely representativeof the
population of the UK and so the results are likely to be
highly generalisable.Apotentialweaknessmight relate
to the quality of the clinical data. Drug prescriptions in
the database are generated by practice computers to
ensure the accuracy of the electronic prescribing
records. Prescription data were highly detailed and
recorded before people developed stroke so there was
no potential for recall bias. Some patients were
probably not taking their prescribed antipsychotics
during periods we classified as exposed, though this
would result only in a reduced effect estimate for
Table 2 | Demographic details of study populations. Figures are numbers of patients andmedians (interquartile ranges)
Patient group (n=6790)
First exposure Duration of
available data
(years)
Age at first
exposure (years)
Age at time of
stroke (years)
Duration of
antipsychotic
exposure (years)Before stroke After stroke
Any antipsychotic drug 4336 2454 6.1 (3.1-9.8) 80.0 (72.7-86.1) 80.7 (73.0-86.8) 0.37 (0.10-1.23)
Dementia before stroke 1276 147 4.1 (2.1-7.5) 82.1 (76.8-87.1) 83.7 (78.6-88.5) 0.68 (0.22-1.55)
No dementia before stroke 3060 2307 6.7 (3.6-10.2) 79.2 (71.1-85.8) 79.3 (71.6-86.2) 0.30 (0.08-1.11)
Typical antipsychotic drug only 3845 2040 5.9 (3.1-9.3) 80.1 (72.6-86.2) 80.9 (73.4-87.0) 0.33 (0.08-1.18)
Atypical antipsychotic drug only 179 277 7.2 (3.0-11.1) 80.3 (73.8-86.4) 79.6 (72.6-85.3) 0.29 (0.09-0.76)
Dementia before stroke + typical
antipsychotic drug only
1092 120 4.0 (2.1-7.0) 82.5 (77.0-87.2) 83.9 (78.8-88.7) 0.64 (0.21-1.51)
Dementia before stroke +
atypical antipsychotic drug only
67 18 4.9 (1.8-10.9) 80.6 (76.3-87.7) 80.8 (76.4-87.9) 0.46 (0.19-0.96)
No dementia before stroke +
typical antipsychotic drug only
2753 1920 6.4 (3.5-9.9) 79.2 (70.9-85.8) 79.8 (71.7-86.3) 0.26 (0.08-1.04)
No dementia before stroke +
atypical antipsychotic drug only
112 259 7.8 (4.0-11.2) 80.3 (73.3-86.2) 78.9 (71.6-84.6) 0.23 (0.08-0.71)
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antipsychotic drug exposure. There might have been
some inaccuracy in our estimation of exposed and
unexposed periods. We addressed this issue by
measuring the relative risk of stroke during sequential
periods after treatment, and, reassuringly, during these
periods the relative risk fell consistently towards unity.
Our analysis also suggests that the risk of stroke might
not fall to baseline until sixmonths after a patient stops
taking an antipsychotic drug.
The validity of the clinical data included in the
database has repeatedly been shown to be high.13 The
rates for recorded strokeare comparablewith estimates
obtained from other epidemiological studies.14 The
database has been widely used to study the epidemiol-
ogy of stroke, with over 15 published papers (such as
those by Smeeth et al,15 Mulnier et al,16 and
Andersohn17), including the replication of results
from two large randomised trials.18 19 We chose not to
include less serious outcomes related to stroke, such as
transient ischaemic attack, as the ascertainment rate
and accuracy of dating for these events is probably less
reliable.Over 85%of the strokes identified in this study
were recorded with codes that did not specify the
subtype of stroke. Nevertheless, we carried out a
subgroup analysis in the 233 patients with designated
haemorrhagic stroke. The rate ratio for this subgroup,
considering exposure to any type of antipsychotic
drug, was 1.14 (0.71 to 1.84), indicating that the effect
might be limited to non-haemorrhagic stroke.
We were unable to investigate possible mechanisms
by which antipsychotics might cause stroke or why the
risk seems to be greater with atypical antipsychotics. It
is unclear if the effect represents a direct vascular
toxicity or whether stroke might be a consequence of
other well established side effects such as weight gain.
To further investigate weight gain as a possible
mechanism,we conducted a subgroup analysis censor-
ing follow-up for each patient after the first three
months of exposure to any antipsychotic drug, as
weight gain is unlikely to substantially alter the risk of
strokewithin such a short timeframe.The resultant rate
ratio was 2.66 (2.34 to 3.02), suggesting the effect is
present shortly after a patient starts taking an anti-
psychotic drug. More information on a possible
mechanism would be useful as further insight could
facilitate effective minimisation of risk. Another
possible limitation of the study design is that time
varying confounders can be difficult to take into
account. Initiation of an antipsychotic drug might
also be associated with a change in exposure status for
some other independent risk factor for stroke, such as a
change in tobacco or alcohol consumption. While we
have successfully controlled for age, data within the
database do not generally allow precise measurements
of subtle changes in behaviour patterns such as
smoking and drinking.
Results in context
Our results on the association between atypical
antipsychotics and stroke are generally consistent
with the results of previous placebo controlled clinical
trials and observational studies, suggesting residual
confounding is unlikely to be a major problem.124-6 20
While few patients with dementia received atypical
antipsychotics in our study and power is therefore
reduced, the point estimate for the effect of atypical
antipsychotics in this group is nearly 6, while the
estimate from the risperidone clinical trial meta-
analysis in such patients was 3.32 (1.43 to 7.70).20 Our
estimate has wide confidence intervals, ranging from
3.01 to 11.38 and is therefore consistent with the effect
seen in clinical trials. It is also consistent, however,with
a more pronounced effect, which could reflect a
genuinely different effect of atypical antipsychotics
under less well controlled conditions than those
attained in clinical trials. Before our study, the risk of
stroke associated with typical antipsychotics was not
clear. For example, the case-control study conducted
by the UK’s Medicines and Healthcare Products
Regulatory Agency (MHRA) suggested a stronger
effect of risperidone on stroke than other anti
psychotics20 but did not compare the effect of typical
with atypical antipsychotics. We have established that
all types of antipsychotics carry an increased risk,
Table 3 | Case series analysis for antipsychotic drugs: association between exposure and stroke.
Figures are rate ratios (95%confidence intervals)
Any antipsychotic drug Typical only† Atypical only†
All patients (n=6790)
No on group 6790 5885 456
Exposed v unexposed
periods
1.73 (1.60 to 1.87) 1.69 (1.55 to 1.84) 2.32 (1.73 to 3.10)
Days after treatment:
1-35 1.73 (1.56 to 1.91) 1.69 (1.52 to 1.89) 1.81 (1.15 to 2.85)
36-70 1.66 (1.44 to 1.90) 1.63 (1.41 to 1.89) 2.22 (1.23 to 4.03)
71-105 1.61 (1.37 to 1.90) 1.57 (1.32 to 1.87) 1.29 (0.52 to 3.23)
106-140 1.23 (1.01 to 1.51) 1.27 (1.03 to 1.56) 0.32 (0.05 to 2.34)
141-175 1.06 (0.84 to 1.33) 1.06 (0.83 to 1.35) 0.76 (0.19 to 3.13)
Patients with recorded dementia (n=1423)
No in group 1423 1208 85
Exposed v unexposed
periods
3.50 (2.97 to 4.12) 3.26 (2.73 to 3.89) 5.86 (3.01 to 11.38)
Days after treatment:
1-35 4.03 (3.34 to 4.87) 3.74 (3.05 to 4.59) 5.70 (2.50 to 12.98)
36-70 3.04 (2.33 to 3.96) 2.92 (2.20 to 3.88) 4.41 (1.40 to 13.89)
71-105 2.71 (1.97 to 3.73) 2.40 (1.69 to 3.41) 3.50 (0.76 to 16.25)
106-140 2.14 (1.45 to 3.15) 2.16 (1.44 to 3.23) 2.21 (0.28 to 17.34)
141-175 1.53 (0.95 to 2.44) 1.49 (0.90 to 2.44) 2.40 (0.30 to 18.88)
Patients without recorded dementia (n=5367)
No in group 5367 4673 371
Exposed v unexposed
periods
1.41 (1.29 to 1.55) 1.40 (1.26 to 1.54) 1.90 (1.36 to 2.65)
Days after treatment:
1-35 1.30 (1.14 to 1.47) 1.30 (1.14 to 1.49) 1.28 (0.72 to 2.30)
36-70 1.42 (1.20 to 1.67) 1.41 (1.18 to 1.67) 2.04 (1.01 to 4.11)
71-105 1.43 (1.18 to 1.73) 1.44 (1.18 to 1.76) 1.02 (0.32 to 3.25)
106-140 1.08 (0.85 to 1.37) 1.11 (0.87 to 1.43) NA
141-175 0.98 (0.75 to 1.28) 0.99 (0.75 to 1.30) 0.50 (0.07 to 3.62)
NA=not applicable (no events).
†Patients who received both typical and atypical antipsychotics not included in this analysis.
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although the risk might be somewhat higher with the
atypical drugs.
As the background risk of stroke in elderly patients is
relatively high,21 we reaffirm that the risks associated
with antipsychotic drug use in patients with dementia
generally outweigh the potential benefits, and use of
antipsychotic drugs in these patients should be avoided
whenever possible. When the use of antipsychotic
drugs is deemed necessary, our results indicate that
typical antipsychotics are preferable to atypical anti-
psychotics with respect to serious cerebrovascular
outcomes. By contrast, our results suggest a much
more modest association between antipsychotics and
stroke in patients without dementia, regardless of age
(1.41, 1.29 to 1.55). This implies that the use of
antipsychotics might be acceptable in elderly patients
without dementia, although as with all treatment
choices, a wider consideration of all potential risks
and benefits would need to be taken into account.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Atypicalantipsychoticsmight increase the riskofstroke inelderlypatients,but thisassociation
could be due to unmeasured or uncontrolled confounding
The extent to which typical antipsychotics are associated with an increased risk of stroke and
whether the effect is the same in patients with dementia as those without is not known
WHAT THIS STUDY ADDS
Both typical and atypical antipsychotic drugs are associated with an increased risk of stroke
and this association is unlikely to be caused by confounding
The risk of stroke in patients receiving antipsychotics seems to be greater in those with
dementia than those without
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